The first three episodes established the foundation – anatomy, risk groups, workup, and surveillance. Now, we begin treatment. This episode explores the physics and biology of dose delivery to the prostate. We'll cover three key areas: First, the benefits of higher doses for biochemical control and what long-term data reveals about distant metastasis and cancer-specific mortality. Second, the rise of moderate hypofractionation as the standard of care, including supporting trials, radiobiologic principles, and important toxicity signals. Third, the FLAME concept – boosting the MRI-visible dominant lesion – and the importance of prioritizing OAR constraints.